Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms

Leukemia Research
J BerdejaA T Gerds

Abstract

The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are associated with increases in janus kinase 2 (JAK2) signaling, often resulting from the JAK2 V617F mutation. LY2784544 (gandotinib) is a potent, selective, small-molecule inhibitor of JAK2 that has potential dose-dependent selectivity for the JAK2 V617F mutation and may inhibit additional JAK2 mutant isoforms in nonclinical testing. A multicenter, single-arm, outpatient phase 2 study evaluated the efficacy, safety, and pharmacokinetics (PK) of gandotinib administered to patients (120 mg once daily) with MPNs, including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). Between May 2012 and March 2015, 138 patients received at least one dose of study drug. Most frequent Grade 3 or 4 treatment-emergent adverse events that were considered study-drug related were anemia (11.6%), hyperuricemia (3.2%), fatigue (2.9%), diarrhea (2.2%), and thrombocytopenia (2.2%). Overall response rates (ORRs) in patients with JAK2 V617F-mutated PV, ET, and MF were 95%, 90.5%, and 9.1%, respectively, while patients with ET and MF without the JAK2 V617F mutations had ORRs of 43.7% and 0%, respectively. LY2784544 demonstrated efficacy in JAK2 V617F-m...Continue Reading

References

Feb 3, 2007·The New England Journal of Medicine·Linda M ScottAnthony R Green
May 26, 2007·Seminars in Thrombosis and Hemostasis·Ayalew Tefferi, Michelle Elliott
Jul 13, 2007·Leukemia·A M VannucchiUNKNOWN MPD Research Consortium
Aug 23, 2007·Blood·Giovanni BarosiUNKNOWN Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis
Mar 3, 2009·Haematologica·Susanne SchnittgerTorsten Haferlach
Apr 9, 2010·Journal of the International Neuropsychological Society : JINS·Katherine J BangenMark W Bondi
Mar 2, 2012·The New England Journal of Medicine·Srdan VerstovsekHagop M Kantarjian
Jul 13, 2013·The Oncologist·Elizabeth R PlimackS Gail Eckhardt
Dec 3, 2014·Hematology/oncology Clinics of North America·Rachel B Salit, H Joachim Deeg
Jan 30, 2015·The New England Journal of Medicine·Alessandro M VannucchiSrdan Verstovsek
Feb 20, 2015·Hematology·Jyoti Nangalia, Tony R Green
May 21, 2015·American Society of Clinical Oncology Educational Book·Jean-Jacques Kiladjian

❮ Previous
Next ❯

Citations

May 6, 2019·Expert Opinion on Emerging Drugs·Lucia Masarova, Srdan Verstovsek
May 6, 2020·Expert Opinion on Therapeutic Targets·Niccolò BartalucciAlessandro M Vannucchi
Feb 20, 2020·Journal of Cellular Physiology·Arezoo HosseiniBehzad Baradaran
Sep 26, 2020·Molecular Cancer·Sailan ZouXianghui Fu
Apr 8, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Massimo GadinaJohn J O'Shea
Jan 23, 2020·Cancers·Marie Brachet-BotineauFabrice Gouilleux
Dec 10, 2020·Expert Opinion on Drug Metabolism & Toxicology·Karima AlimOlivier Fardel
Dec 18, 2020·Expert Opinion on Drug Safety·Giacomo Coltro, Alessandro M Vannucchi
May 30, 2021·Biomarker Research·Rory M Shallis, Nikolai A Podoltsev
May 1, 2021·European Journal of Immunology·Francesca Romana SpinelliMassimo Gadina
Jun 18, 2021·JCI Insight·Pegah Mehrpouya-BahramiElena V Galkina
Jun 29, 2021·Arthritis & Rheumatology·Christine LiuJohn J O'Shea
May 12, 2020·International Archives of Allergy and Immunology·Farhad SeifDavood Mansouri
Nov 27, 2021·Signal Transduction and Targeted Therapy·Xiaoyi HuWei Wang
Aug 22, 2020·The International Journal of Biochemistry & Cell Biology·William A HallMarja T Nevalainen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.